Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01639248 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
A Phase 2 study, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01639248 is a Phase 2 study that has completed, run by CASI pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT01639248, a Phase 2 study, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the activity of ENMD-2076 as defined by the clinical benefit rate when patients with previously treated locally advanced or metastatic triple negative breast cancer are treated with daily oral ENMD-2076.
Interventions
- DRUG ENMD-2076
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-07 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01639248
The ClinicalTrials.gov registry entry for NCT01639248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CASI pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ENMD-2076 is the first listed.
NCT01639248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01639248 about?
NCT01639248 is a clinical study titled "Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC". The purpose of this study is to determine the activity of ENMD-2076 as defined by the clinical benefit rate when patients with previously treated locally advanced or metastatic triple negative breast cancer are treated with daily oral ENMD-2076.
What is the current status of trial NCT01639248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2012-07. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01639248?
The interventions under investigation include: ENMD-2076 (DRUG).
Who is sponsoring clinical trial NCT01639248?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.